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Summary A monoclonal antibody (H17E2) was used in a solid-phase localisation of enzyme activity (ILEA)
assay to evaluate placental-like alkaline phosphatase (PLAP) as a serum marker of testicular germ cell
tumours. Single or repeated assays were performed on 213 normal blood donor and a smaller number of term
pregnancy and testicular cancer sera. The detection limit of PLAP by this system was 0.14O.D. units
equivalent to 0.04iu - 1. Of 50 patients with established metastatic disease tested before treatment, 88% of 16
with seminoma, 54% of 13 with mixed seminoma and malignant teratoma and 33% of 21 with malignant
teratoma had serum PLAP>0.2 O.D. units. This compared to an incidence of 2% in non-smokers and of 29%
in smokers who had been free of disease for more than 12 months. In 15 of 22 successfully treated patients,
pre-treatment serum PLAP exceeded 0.2 O.D. units (mean 0.69 O.D.) and varying (53-97%) reductions in the
initial levels occurred with treatment. These results with monoclonal antibody ILEA assay suggest that
measurement of PLAP levels will be useful in the management of patients with germ cell tumours, particularly
seminoma.
Monitoring of serum alpha-foetoprotein (AFP) and
human chorionic gonadotrophin (fl-HCG), plays a
major role in assessing the effects of treatment in
patients with metastatic malignant teratomas
(Raghavan et al., 1980; Lange, 1982; Newlands et
al., 1983) as well as enabling new innovations to be
introduced into treatment of patients who present
without metastases (Peckham et al., 1983; Oliver et
al., 1983b).
The development of such approaches in the
management of patients with seminoma has been
restricted because of the lack of a reliable marker
of the disease activity. Several studies using poly-
clonal antisera have detected the presence of sub-
stantial amounts of placental alkaline phosphatase
(PLAP) in both tumour tissue and serum of semi-
noma patients (Wahren et al., 1979; Uchida et al.,
1981; Lange et al., 1982; Jeppsson et al., 1983; Dass
& Bagshawe, 1984; Nustad et al., 1984). However,
the demonstration that smoking can produce false
positive reactions (Tonik et al., 1983; Maslow et al.,
1983) and the increasing evidence (Millan &
Stigbrand, 1983; Paiva et al., 1983) of the com-
plexity ofthe genetic control ofalkaline phosphatase
expression, has made it difficult to interpret the
results of these investigations.
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A new approach to overcoming such problems
has been the development of monoclonal antibodies
(MAB) to PLAP. One of these, ICRF-H17E2,
produced by initial immunization with term
placental membranes (Travers & Bodmer, 1984;
McLaughlin et al., 1984), reacts with a heat
resistant alkaline phosphatase that is more easily
inhibitable by phenyl-alanyl-glycyl-glycine than L-
leucine, thus, confirming that it recognises term
PLAP. However, when compared with another
anti-PLAP MAB (H317), H17E2 has additional
reactivity with a L-leucine inhibitable PLAP-like
alkaline phosphatase which can be extracted from
normal testis (McLaughlin et al., 1984). The
monoclonal H17E2 also has been shown to react
strongly with the surface membranes of all of a
small number of germ cell tumours of the testis
(Epenetos et al., 1984).
It was therefore decided to use an assay based
upon immunolocalisation of enzyme activity
(ILEA), to evaluate the potential of H17E2 MAB
serum assay for monitoring the treatment of
patients with germ cell tumours of the testis. This
paper reports the initial results of this study.
Materials and methods
Serum samples
These were selected from a bank of preserved
(-20°C) specimens that had been collected since
1979 from patients with seminoma and other
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testicular germ cell tumours. The staging of disease
in these patients and their treatment with con-
ventional cis-platinum containing chemotherapy
regimens, has been reported elsewhere (Oliver et al.,
1980, 1983a). The histological classification of these
tumours was according to the system of the British
Testicular Tumour Panel (Pugh & Cameron, 1976).
All sera received for PLAP-like AP determinations
had, in addition, been assayed for /3-HCG, AFP
and hydroxybutyric dehydrogenase (HBD). An
assay for the latter enzyme was included with the
established markers, because of its close
relationship to lactic dehydrogenase which is known
to be elevated in patients with testicular tumours.
Control sera were from two sources: Red Cross
donor samples remaining after routine Australia
antigen screening and females from Guernsey in
whom smoking history was known.
Monoclonal antibody H17E2
This murine IgG1 antibody was derived from a
hybridoma produced after initial immunisation with
purified plasma membranes of normal term
placenta. It has been characterised (Travers &
Bodmer, 1984) as reacting with all forms of heat
stable PLAP, but not with the liver or intestinal
isoenzymes of alkaline phosphatase.
Immunolocalisation ofenzyme activity (ILEA) assay
Serum PLAP-like AP was determined in healthy
individuals and patients with cancer, essentially as
Microtitre Plate wells
(Flexible PVC: Dynatech)
outlined in Figure 1. Optimal conditions for the
assay were established by systematic variation of
the coating antibody and test sample concentration
and the various incubation times. Routinely, H17E2
MAB was adsorbed to plate wells by overnight
incubation at 40C with 100 ,u1 (358 ng) of a
ProteinA affinity purified preparation (Hudson &
Hay, 1980) in PBS. Unbound antibody was
removed by washing with 0.05% Tween-20 in PBS,
before addition of 100pI aliquots of undiluted
serum which were tested in duplicate. After
incubation for 2 h at room temperature and further
washing, the activity of the enzyme localised by the
solid phase antibody was determined colorimetric-
ally with Sigma 104 phosphatase substrate (100Mil
per well of a 1 mgml-I solution in 0.2M diethanol-
amine containing 5 mM MgCl2, pH 9.8). To develop
the colour reaction, the plates, covered in
aluminium foil, were incubated at 37°C for 2 h and
then left overnight (16-17 h) at room temperature.
For each assay, a calibration curve (Figure 2) was
constructed with doubling dilutions of a normal
term pregnancy serum. The heat stable PLAP activity
(Sigma Unitsml-1) of the standard pregnancy
serum was estimated by direct colorimetric
determination (Sigma 15-min assay, Kit No. 104).
A Sigma Unit is defined as that amount of enzyme
activity that will liberate 1 4mol of p-nitrophenol
per hour under the stated test conditions. Values
expressed in Sigma Unitsml-l were converted to
International Units (iul-1) by multiplying by 16.7
as described in the assay kit instructions (Sigma
technical bulletin No. 104).
coated overnight at4°C with
Anti-PLAP Ab (H17E2)
W.
Wells washed x3, samples or standard added and plate incubated
at room temperature for 2 hours
+ ,
Further x3 wash, then substrate added to determine enzyme activity
+ SuBssTR_ATEJ O.D. 405 V +2 ors3° Titertek
n)-NitrnDhenvl 2 or 7C Multiscan
phosphate
disodium
then overnight
at room temperature
Figure 1 Determination of serum PLAP-like AP by immunolocalisation of enzyme activity (ILEA) assay.PLAP AS A SERUM MARKER OF TESTICULAR TUMOURS 633
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Figure 2 Variability associated with repeated ILEA
assay of the same reference pregnancy serum.
Results
Sensitivity and reproducibility ofILEA assay
Each test run included a doubling dilution series of
a reference near-term pregnancy serum made from
stock aliquots (100pl) of sera kept until use at
-70°C. Figure 2 shows the results of 9 separate
assays of the same pregnancy serum over a period
of 6 months, with optical absorbance at 405 nm
plotted on a log scale against enzymatic activity
converted from Sigma Unitsml-l to International
Units (iu - 1) (see Methods).
The variability at a fixed dilution is fairly
constant on a logarithmic scale over the range and
gives a coefficient of variation (C.V.) in the original
units of + 11.0%. However, it will be seen that
there are substantial consistent differences between
the 9 assays. It would thus be possible to eliminate
part of this between-assay variability by using as
standards for calibration, stored aliquots from a
single dilution series of a large pregnancy serum
pool. This would reduce the between-assay
variability to a C.V. of +6.3%.
The background absorbance in these assays
averaged 0.07O.D. for wells (n=61) in which PBS
was substituted for the test sera. Accordingly twice
the background (0.140.D.) was considered to be
the practical lower limit of detection of PLAP
activity, an O.D. value corresponding to 0.04iu 1-
(Figure 2).
The results of selected sera from patients were
similarly analysed to provide comparable estimates
of inter-test variability both on single repeat testing
(13 subjects) and serial sample testing during
sustained remission (22 subjects; 2-7 samples each).
For the blind re-testing figures the estimated C.V.
of a single reading (the mean of 2 replicates) was
+15.4%, whereas the repeated sample data gave a
within-subject C.V. of +20.0%. Both th*e
estimates of variability eliminate consistent
differences between the results of successive assays,
and so they should be compared with the reference
serum assay variability of +6.3%. The larger C.V.
of serial readings is most likely a result of genuine
physiological changes within an individual from one
time to another.
Serum PLAP-like AP levels in patients and controls
Sera from two-hundred-and-thirteen Red Cross
blood donor controls and from 50 patients with
established metastatic testicular germ cell tumours
were tested. The distribution of serum PLAP-like
AP is shown in Figure 3. There were no significant
differences between male and female control sera
(Figure 3a), and the greater proportion (85% and
80% respectively) had assay readings in the range
up to 0.2O.D. The remaining group had a mean
value of 0.36O.D. in the case of the 24 male sera
and 0.32O.D. for the 11 female sera. The smoking
habits of these 35 control individuals were
ascertained, where possible, by postal questionnaire.
This showed that 10 of the 24 male sera, and 7 of
the 11 female sera with PLAP-like. AP values
>0.20.D., came from smokers. A further 3 male
sera and 1 female serum were from ex-smokers but
for the rest of the groups (11 males and 3 females)
smoking details could not be obtained. Additional
evidence for a smoking effect was obtained from a
second control group, viz: 53 females from
Guernsey, in whom smoking history was known
(Figure 4). The data suggest a progressive mean rise
in serum PLAP-like AP with increased smoking.
This trend is highly significant (P=0.0001) as
determined by a Wilcoxon rank regression test
(Cuzick, in press).
In contrast, in the 50 patients with established
metastatic disease (Figure 3b) serum values
exceeding 0.2O.D. were detected in 14 of the 16
with seminoma (88%), 7 of the 13 with mixed634 D.F. TUCKER et al.
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Figure 3 Distribution of serum PLAP-like AP levels in control blood donors (a) and pre-treatment groups of
patients with metastatic testicular cancer (b). See calibration curve (Figure 2) for conversion of O.D. readings
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Figure 4 Effect of smoking on serum PLAP-like AP
in a female control population. See calibration curve
(Figure 2) for conversion of O.D. readings to iu1-1.
seminoma and malignant teratoma (54%) and 7 of
the 21 with malignant teratoma (33%). Details of
the range of serum PLAP-like AP levels associated
with each of these different tumour sub-types
examined, are given in Figure 5. Again by
Wilcoxon rank regression test, a significant
(P =0.002) trend was found for the frequency 'of
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Figure 5 Individual serum PLAP-like AP values
determined in patients (Figure 3b) with different
metastatic tumour sub-types. See calibration curve
(Figure 2) for conversion of O.D. readings to iul-1.
(0) non-smoker; (0) smoker; (A) ex-smoker.
elevated serum PLAP-like AP to be greater in
seminoma than in mixed seminoma and malignant
teratoma patients, and also in the latter group
compared with the combined patients affected with
various types of malignant teratoma.
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Effect oftreatment on serum PLAP-like AP levels
Table I shows several examples, in the different
patient groups studied (Figure 3b, Figure 5), of
serum PLAP-like AP determined before and after a
successful course of treatment. Seven of these
patients had moderate to marked (0.47-2.00 O.D.)
elevations of PLAP-like AP before treatment, and a
clear-cut (81-97%) reduction was apparent on
achieving complete clearance of tumour. In the one
patient who relapsed, a return to a positive reaction
was detected by continued serial serum assay.
Lesser (53-79%) reductions in PLAP-like AP could
also be demonstrated in 10 of the remaining 15
patients. These decreases were smaller in percentage
Table I Changes in pre- and post-treatment
serum PLAP-like AP according to tumour sub-
type and smoking status.
Serum PLAP-like AP
(O.D. values)a
Smoking Pre- Post- Disease
status treatment treatment statusb
Seminomas
S 2.0 0.06 CRC
S 1.4 0.24 CR
Ex-S 1.29 0.24 CR
S 0.47 0.06 CR
S 0.26 0.08 3 months
S 0.25 0.10 CR
Ex-S 0.21 0.09 CR
Mixed tumours
Non-S 1.5 0.09 CR
S 0.93 0.14 CR
Non-S 0.26 0.15 CR
S 0.20 0.09 CR
Non-S 0.21 0.09 4 months
Non-S 0.14 0.06 2 months
Non-S 0.09 0.08 10 months
Non-S 0.11 0.09 CR
MTU
Non-S 0.21 0.07 CR
Non-S 0.09 0.06 CR
MTI
Non-S 0.13 0.06 1 month
S 0.28 0.06 6 months
Ex-S 0.17 0.09 CR
Unclassified
S 0.79 0.13 CR
S 0.32 0.15 CR
aOptical absorbance at 405 nm. See calibra-
tion curve (Figure 2) for conversion of O.D.
readings to iu l.-.
bAssessed at 12 months unless otherwise stated.
CCR =Complete remission. No evidence of
disease at 12 months.
terms as the initial levels did not exceed 0.32O.D.
and the final values were only slightly less than the
group above. Of the 5 patients with virtually
unchanged serum PLAP-like AP, 4 were non-
smokers and the other was an ex-smoker. A
separate review of the smoking history of all
patients in remission whose sera have been tested,
established that the proportion of patients with
sustained levels above 0.2 O.D. was greatest in
smokers, intermediate in ex-smokers and lowest in
non-smokers (29%, 17% and 2%, respectively).
Correlation ofPLAP-like AP expression with other
tumour markers
In addition to determining PLAP-like AP levels,
pre-treatment sera from 32 of the patients included
in this study, were also assayed for fl-HCG, AFP
and HBD. The results were analysed for a
correlation of PLAP-like AP expression with these
other tumour markers, using as the criteria for
marker positivity, serum levels of >0.4 O.D. for
PLAP-like AP, >lOkuI-I AFP, >1 IMgl.-I HCG
and >200iu -1 HBD. A raised serum PLAP-like
AP was not found to be significantly associated
(Yates corrected x2 test) with either AFP, fl-HCG
or HBD, though, with one exception, all patients
with elevated PLAP-like AP also had elevated HBD
(Table II).
Table II Correlation between PLAP-like AP,
alpha-foetoprotein, fl-human chorionic
gonadotrophin and hydroxybutyric dehydro-
genase production in patients with testicular
cancer.
Total N AFP HCG HBD
32 + - + - + -
PLAP- + 0 8 4 4 7 1
LIKE AP - 9 15 11 13 12 12
x2=2.52 x2=0.04 x2=2.12
Discussion
Placental alkaline phosphatase was one of the first
examples of the class of proteins now classified as
oncofoetal antigens. The original report was from a
patient with squamous cell carcinoma of the lung
(Fishman et al., 1968a), though subsequently
similar aberrant expression was demonstrated in a636 D.F. TUCKER et al.
small proportion of tumours from other sites such
as bone marrow (Damle et al., 1979), breast (Wada
et al., 1979), gut (Skinner & Whitehead, 1981) and
gonad (Wahren et al., 1979; Uchida et al., 1981;
Lange et al., 1982; Haije et al., 1979). The enzyme
produced by the original patient's tumour (the
Regan variant) was indistinguishable by catalytic
and immunological criteria from the normal term
placental enzyme (PLAP) (Fishman et al., 1968b).
However, as the phenomenon became more widely
recognised, other PLAP variants (Nagao- and
Kashara-type (Nakayama et al., 1970; Higashino et
al., 1972)) were discovered. Subsequent detailed
immunochemical studies of these variants suggested
that they 'were either the products of other, less
frequent, alleles of the PLAP locus (D for Nagao-
type) (Inglis et al., 1973) or were related to a form
occurring in hepatoma patients and normal FL
amnion cells (Kasahara-type (Higashino et al.,
1975)).
While it has been possible with polyclonal
antisera to demonstrate that most seminomas
express PLAP (Wahren et al., 1979; Uchida et al.,
1981; Lange et al., 1982; Jeppsson et al., 1983), the
identity of the particular variant involved remains
uncertain. The results from a recent study of
normal testis alkaline phosphatase using MABs to
PLAP, suggest that the testis expresses a form of
alkaline phosphatase which is controlled by a
separate genetic locus (Millan & Stigbrand, 1983).
Although this putative testis locus has different
alleles to the PLAP locus, cross-reactions of testis
type enzymes with some of the anti-PLAP mono-
clonal reagents can occur (Millan & Stigbrand,
1983). This enzyme in current parlance is described
as testicular placental alkaline phosphatase-like
alkaline phosphatase (testicular PLAP-like AP).
Recent studies of the reactivity of the MAB H17E2
used for the present serum assays, have
demonstrated that it recognizes both testicular
PLAP-like AP and PLAP (Travers & Bodmer,
1984; McLaughlin et al., 1984). Further preliminary
analysis suggests that this antibody is monomorphic
as it reacts with the products of all the frequent
PLAP alleles (Harris, personal communication).
However, its full pattern of reactivity with all the
alleles of the testicular PLAP-like AP locus still
remains to be established.
Despite these caveats, the data presented herein
confirm earlier studies using polyclonal antibody-
based assays that serum PLAP-like AP is markedly
elevated in the majority of patients with metastatic
seminoma, and returns to normal after successful
treatment (Wahren et al., 1979; Uchida et al., 1981;
Lange et al., 1982; Jeppsson et al., 1983; Dass &
Bagshawe, 1984; Nustad et al., 1984). Furthermore,
in the present and two similar studies (Horwich et
al., 1985; Epenetos et al., 1985) H17E2 immuno-
assay has detected positive reactivity in 88-100% of
seminoma patients with active disease, a substantial
improvement on the 50-71% positive rate observed
with the aforementioned polyclonal antibody
assays. In two previous reports (McLaughlin &
Johnson, 1984; Millan et al., 1982), H17E2 and Fl1
monoclonal immunoassay detected a lower
incidence of, respectively, 4/9 and 3/6 seminoma
patients with raised serum PLAP, although in both
these investigations clinical details supporting the
existence of metastases were lacking.
Two new observations also have been made in
the course of the present serum marker evaluations.
First, elevated levels in patients with malignant
teratoma occurred more frequently if there was a
mixed tumour with both seminoma and teratoma
components. Thus, H17E2 MAB assay may also
have potential in estimating the relative proportion
of seminoma present in the metastases in these
patients. The second observation relates to the
failure to detect PLAP-like AP in sera of two
patients, who had extensive metastatic malignant
teratoma trophoblastic (MTT) and markedly
elevated serum human fl-HCG associated with their
disease. It is possible that such patients' tumours
are showing less than complete placental
differentiation, or have failure of secretion of
intracellular products. The latter explanation
accords with the absence of raised PLAP-like AP in
18 sera (kindly supplied by Professor Bagshawe)
from female patients with highly elevated P-HCG
due to metastatic choriocarcinoma (Tucker,
unpublished). A failure of secretion rather than
expression is also consistent with the reported intra-
cellular detection of a L-phenylalanine and L-leucine
inhibitable form of PLAP by the choriocarcinoma
line BEWO (Speeg et al., 1977). Alternatively, the
lack of circulating PLAP-like AP could be due to
the tendency of MTT to express the products of
early gestational trophoblast rather than those
which appear predominantly after the first
trimester. However, in one of these two MTT
patients immunocytochemical staining of the
tumour tissue demonstrated a high content of
H17E2 reactive PLAP-like AP, even though the
serum level of the enzyme was within normal limits
(0.18 O.D.; Figure 5). Further study of this type of
case may help clarify whether real differences do
exist between the neoplastic expression and release
of PLAP-like AP in seminoma and malignant
teratoma.
Another clinically interesting finding is the one
patient with metastatic seminoma who had serum
AFP of 14,000 kuI1- and expression of AFP by his
tumour as determined by immunocytochemical
staining. Some investigators have considered the
detection of AFP in the serum of patients with
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occult teratoma (Lange et al., 1980). Others have
regarded the appearance of this marker as
supporting the idea that seminoma is an inter-
mediate pathological state which evolves to either
AFP- or HCG-secreting teratoma (Raghavan et al.,
1982). The PLAP-like AP level in the afore-
mentioned seminoma patient with elevated AFP,
was the lowest of all the patients with seminoma
(0.06 O.D.; Figure 5). In addition, in the analysis of
the patients with established metastases, there was a
suggestion of a negative association of PLAP-like
AP and AFP expression (Table II). These
observations may be a reflection of an interaction
between the genes controlling expression of these
two cellular products, though study of a larger
number of these rare AFP-producing seminomas is
clearly necessary.
Previous reports (Tonik et al., 1983; Maslow
et al., 1983) that smoking is an important con-
tributory factor to raised levels of serum PLAP-
like AP, have been substantiated by the present
data obtained from patients in remission and both
Guernsey and Red Cross Blood donor control
populations. A history of smoking clearly limits the
use of serum PLAP-like AP determinations to
monitor patients with seminoma after treatment.
However, serial assay in remission patients, even if
they were smokers, was very reproducible so this
should still provide a useful adjunct to radiological
examinations for follow-up studies. Further
investigations of the underlying causes of the
increased levels in smokers will be required in order
to improve the specificity of the assay and better
understand the patho-physiological effects of
smoking.
From a practical standpoint, it is important that
the high specificity of the MAB HI7E2 is
exploitable in the ILEA assay with an inter-test
reproducibility of PLAP-like AP measurements
much the same as previously reported for
polyclonal antibody ELISA (Mill'an & Stigbrand,
1981). These ELISA-type assays also compare
favourably with radioimmunoassay, where within
assay coefficients of variation for replicates of 3-
8%, and between repeats of the same sample on
different occasions of 8-20%, have been reported
(Chard, 1982).
There are several potential advantages of the
MAB based technique over radioimmunoassay,
which should remain applicable with its adaptation
to other tumour markers. In particular, ILEA assay
does not require the special precautions and
separation steps necessary for assays using radio-
active material. The simplicity and sensitivity (down
to 200 ng -1; P. Davis, personal communication) of
the method together with easy automation of end-
point reading should also make individual tests
more cost effective. The ILEA assay clearly satisfies
the main need for testis tumour marker monitoring
of a simple, reliable and rapid technique available
on site at the hospitals patients are attending for
treatment. However, the economy possible with
ILEA assay will be realized only where there is a
greater demand for frequent serum PLAP-like AP
assessment, such as exists in Regional Centres
treating larger numbers of patients.
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Hardwick of the Red Cross for help with obtaining
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Yong-Lan Pookim for expert technical assistance; Dr
John Masters, Tissue Culture Laboratory, St Paul's
Hospital, for providing assistance with storage and
retrieval of sera; Dr A. Rose, St Paul's Hospital for
performing HBD assays; and Professor T. Chard, St
Bartholomew's Hospital, for performing AFP and HCG
assays and Dr C. Parkinson for histological classification
of the tumours. Our thanks are also due to Linda Hayes
and Audrey Becket for assistance with preparation of the
manuscript.
References
CHARD, T. (1982). An introduction to radioimmunoassay
and related techniques. Characteristics of binding
assays-precision. In: Laboratory Techniques in Bio-
chemistry and Molecular Biology Vol. 6, Part 2. (Eds.
Work & Work), Amsterdam: Elsevier, p. 203.
CUZICK, J. (1985). A Wilcoxon-type test for trend. Stat.
Med. (in press).
DAMLE, S.R., SHEETY, P.A., JUSSAWALLA, D.J., BHIDE,
S'V. & BAXI, A.J. (1979). Occurrence of heat-labile
Regan type alkaline phosphatase in hematopoietic
tumors. Int. J. Cancer, 24, 398.
DASS, S. & BAGSHAWE, K.D. (1984). A sensitive, specific
radioimmunoassay for placental alkaline phosphatase.
In: Human Alkaline Phosphatases. Progress in Clinical
and Biological Research, Vol. 166. (Eds. Stigbrand &
Fishman), New York: Alan R. Liss, Inc., p. 49.
EPENETOS, A.A., MUNRO, A.J., TUCKER, D.F. & 6 others.
(1985). Monoclonal antibody assay of serum placental
alkaline phosphatase in the monitoring of testicular
tumours. Br. J. Cancer, 51 (this issue).638 D.F. TUCKER et al.
EPENETOS, A.A., TRAVERS, P., GATTER, K.C., OLIVER,
R.T.D., MASON, D.Y. & BODMER, W.F. (1984). An
immunohistological study of testicular germ cell
tumours using two different monoclonal antibodies
against placental alkaline phosphatase. Br. J. Cancer,
49, 11.
FISHMAN, W.H., INGLIS, N.R., GREEN, S. & 6 others.
(1968a). Immunology and biochemistry of Regan
isoenzyme of alkaline phosphatase in human cancer.
Nature, 219, 698.
FISHMAN, W.H., INGLIS, N.R., STOLBACH, L.L. &
KRANT, M.J. (1968b). A serum alkaline phosphatase
isoenzyme of human neoplastic cell origin. Cancer
Res., 28, 150.
HAIJE, W.G., MEERWALDT, J.H., TALERMAN, A. & 5
others. (1979). The value of sensitive assay of carcino-
placental alkaline phosphatase (CPAP) in the follow-
up of gynaecological cancers. Int. J. Cancer, 24, 288.
HIGASHINO, K., HASHINOTSUME, M., YANG, K.Y.,
TAKAHASHI, Y. & YAMAMURA, Y. (1972). Studies on
a variant alkaline phosphatase in sera of patients with
hepatocellular carcinoma. Clin. Chim. Acta, 40, 67.
HIGASHINO, K., KUDO, S., OHTANI, R., YAMAMURA, Y.,
HONDA, T. & SAKURAI, J. (1975). A hepatoma
associated alkaline phosphatase, the Kasahara
isoenzyme, compared with one of the isoenzymes of
FL amnion cells. Ann. N.Y. Acad. Sci., 259, 337.
HORWICH, A., TUCKER, D.F. & PECKHAM, M.J. (1985).
Placental alkaline phosphatase as a tumour marker in
seminoma using the H17E2 monoclonal antibody
assay. Br. J. Cancer, 51 (this issue).
HUDSON, L. & HAY, F.C. (1980). Isolation of IgG
subclasses using protein A-sepharose. In: Practical
Immunology 2nd Edition, Oxford: Blackwell Sci. Publ.,
p. 223.
INGLIS, N.R., KIRLEY, S., STOLBACH, L.L. & FISHMAN,
W.H. (1973). Phenotypes of the Regan isoenzyme and
identity between the placental D-variant and the
Nagao enzyme. Cancer Res., 33, 1657.
JEPPSSON, A., WAHREN, B., STIGBRAND, T., EDSMYR, F.
& ANDERSON, L. (1983). A clinical evaluation of
serum placental alkaline phosphatase in seminoma
patients. Br. J. Urol., 55, 73.
LANGE, P.H. (1982). Testicular cancer markers. In: Human
Cancer Markers, Vol. 2. (Eds., Sell & Wahren), New
Jersey: Humana Press, p. 259.
LANGE, P.H., MILLAN, J.L., STIGBRAND, T., VESSELLA,
R.L., RUOSLAHTI, E. & FISHMAN, W.H. (1982).
Placental alkaline phosphatase as a tumor marker for
seminoma. Cancer Res., 42, 3244.
LANGE, P.H., NOCHOMOVITZ, L.E., ROSAI, J. & 15 others.
(1980). Serum alpha-fetoprotein and human chorionic
gonadotrophin in patients with seminoma. J. Urol.,
124, 472.
MASLOW, W.C., MUENSCH, H.A., AZAMA, F. &
SCHNEIDER, A.S. (1983). Sensitive fluorometry of
heat-stable alkaline phosphatase (Regan enzyme)
activity in serum from smokers and non smokers. Clin.
Chem., 29, 260.
McLAUGHLIN, P.J. & JOHNSON, P.M. (1984). A search for
human placental-type alkaline phosphatases using
monoclonal antibodies. In: Human Alkaline
Phosphatases. Progress in Clinical and Biological
Research, Vol. 166. (Eds. Stigbrand & Fishman), New
York: Alan R. Liss, Inc., p. 67.
McLAUGHLIN, P.J., TRAVERS, P.J., McDICKEN, I.W. &
JOHNSON, P.M. (1984). Demonstration of placental
and placental-like alkaline phosphatase in non-
malignant human tissue extracts using monoclonal
antibodies in an enzyme immunoassay. Clin. Chim.
Acta, 137, 341.
MILLAN, J.L. & STIGBRAND, T. (1981). "Sandwich"
enzyme immunoassay for placental alkaline phos-
phatase. Clin. Chem., 27, 2014.
MILLAN, J.L. & STIGBRAND, T. (1983). Antigenic deter-
minants of human placental and testicular placental-
like alkaline phosphatases as mapped by monocloncal
antibodies. Eur. J. Biochem., 136, 1.
MILLAN, J.L., STIGBRAND, T., RUOSLAHTI, E. &
FISHMAN, W.H. (1982). Characterization and use of an
allotype-specific monoclonal antibody to placental
alkaline phosphatase in the study of cancer-related
phosphatase polymorphism. Cancer Res., 42, 2444.
NAKAYAMA, T., YOSHIDA, M. & KITAMURA, M. (1970).
L-leucine-sensitive, heat-stable alkaline phosphatase
isoenzyme detected in a patient with pleuritis
carcinomatosa. Clin. Chim. Acta, 30, 546.
NEWLANDS, E.S., RUSTIN, G.J.S., BEGENT, R.H.J.,
PARKER, D. & BAGSHAWE, K.D. (1983). Further
advances in the management of malignant teratomas
of the testis and other sites. Lancet, i, 948.
NUSTAD, K., MONRAD-HANSEN, H.P., PAUS, E., MILLAN,
J.L., N0RGAARD-PEDERSEN & THE DATECA STUDY
GROUP. (1984). Evaluation of a new, sensitive radio-
immunoassay for placental alkaline phosphatase in
pre- and post-operative sera from the Danish testicular
cancer material. In: Human Alkaline Phosphatases
Progress in Clinical and Biological Research, Vol. 166.
(Eds. Stigbrand & Fishman), New York: Alan R. Liss,
Inc., p. 337.
OLIVER, R.T.D., BLANDY, J.P., HENDRY, W.F., PRYOR,
J.P., WILLIAMS, J.P. & HOPE-STONE, H.F. (1983a).
Evaluation of radiotherapy and/or surgico-pathological
staging after chemotherapy in the management of
metastatic germ cell tumours, Br. J. Urol., 55, 764.
OLIVER, R.T.D., HOPE-STONE, H.F. & BLANDY, J.P.
(1983b). Justification of the use of surveillance in the
management of stage I germ cell tumours of the testis.
Br. J. Urol., 55, 760.
OLIVER, R.T.D., ROHATINER, A., WRIGLEY, P.F.M. &
MALPAS, J.S. (1980). Chemotherapy of metastatic
testicular tumours. Br. J. Urol., 52, 34.
PAIVA, J., DAMJANOV, I., LANGE, P.H. & HARRIS, H.
(1983). Immunohistochemical localization of placental-
like alkaline phosphatase in testis and germ cell tumors
using monoclonal antibodies. Am. J. Pathol., 111, 156.
PECKHAM, M.J., BARRETT, A., HORWICH, A. & HENDRY,
W.F. (1983). Orchiectomy alone for stage I testicular
non-seminoma. A progress report. Br. J. Urol., 55,
754.
PUGH, R.C.B. & CAMERON, K.M. (1976). Teratoma. In:
Pathology of the Testis. (Ed. Pugh), Oxford: Blackwell
Sci. Publ., p. 199.
RAGHAVAN, D., GIBBS, J., NOGUEIRA, C.R. & 4 others.
(1980). The interpretation of marker protein assays: a
critical appraisal in clinical studies and a zenograft
model. Br. J. Cancer, 41 (Suppl. IV), 191.PLAP AS A SERUM MARKER OF TESTICULAR TUMOURS 639
RAGHAVAN, D., SULLIVAN, A.L., PECKHAM, M.J. &
NEVILLE, A.M. (1982). Elevated serum alphafeto-
protein and seminoma: clinical evidence for a histologic
continuum? Cancer, 50, 982.
SKINNER, J.M. & WHITEHEAD, R. (1981). Carcino-
placental alkaline phosphatase in malignant and pre-
malignant conditions of the human digestive tract.
Virchows Archiv [A], 394, 109.
SPEEG, K.V., AZIZKHAN, J.C. & STROMBERG, K. (1977).
Characteristics of alkaline phosphatase from two
continuous lines of human choriocarcinoma cells. Exp.
Cell Res., 105, 199.
TONIK, S.E., ORTEMEYER, A.E., SHINDELMAN, J.E. &
SUSSMAN, H.H. (1983). Elevation of serum placental
alkaline phosphatase levels in cigarette smokers. Int. J.
Cancer, 31, 51.
TRAVERS, P. & BODMER, W. (1984). Preparation and
characterisation of monoclonal antibodies against
placental alkaline phosphatase and other human
trophoblast-associated determinants. Int. J. Cancer, 33,
633.
UCHIDA, T., SHIMODA, T., MIYATA, H. & 6 others.
(1981). Immunoperoxidase study of alkaline phos-
phatase in testicular tumors. Cancer, 48, 1455.
WADA, G.H., SHINDELMAN, J.E., ORTEMEYER, A.E. &
SUSSMAN, H.H. (1979). Demonstration of placental
alkaline phosphatase in human breast cancer. Int. J.
Cancer, 23, 781.
WAHREN, B., HOLMGREN, P.A. & STIGBRAND, T. (1979).
Placental alkaline phosphatase, alphafetoprotein and
carcinoembryonic antigen in testicular tumours. Tissue
typing by means of cytologic smears. Int. J. Cancer,
24, 749.